Company Description
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States.
It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market.
Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs.
The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes.
It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry.
In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets.
The company was incorporated in 2021 and is based in Dallas, Texas.
| Country | United States |
| Founded | 2021 |
| IPO Date | Nov 10, 2022 |
| Industry | Chemicals |
| Sector | Materials |
| Employees | 271 |
| CEO | Paul Mann |
Contact Details
Address: 2200 Ross Avenue, Suite 4575E Dallas, Texas 75201 United States | |
| Phone | (214) 432-8219 |
| Website | aspisotopes.com |
Stock Details
| Ticker Symbol | ASPI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1921865 |
| CUSIP Number | 00218A105 |
| ISIN Number | US00218A1051 |
| Employer ID | 87-2618235 |
| SIC Code | 2890 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gerdus Kemp M.D., Ph.D. | Medical Director and Chief Executive Officer of Pet Labs |
| Paul Elliot Mann C.F.A. | Executive Chairman and Chief Executive Officer |
| Heather Kiessling | Chief Financial Officer |
| Robert Ainscow | Chief Operating Officer |
| Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D. | Chief Technology Officer |
| Nicholas Michael Mitchell | Co-Chief Operating Officer |
| Donald George Ainscow | EVice President, General Counsel and Secretary |
| Hendrik T. van Wyk | Head of Engineering |
| Dr. Xandra van Heerden Ph.D. | Head of Research and Development |
| Stefano Marani | President of Electronics and Space |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 13, 2026 | 144 | Filing |
| Apr 13, 2026 | 8-K | Current Report |
| Apr 10, 2026 | 10-K | Annual Report |
| Apr 10, 2026 | 8-K | Current Report |
| Mar 31, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 24, 2026 | 8-K/A | [Amend] Current report |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 10, 2026 | 8-K | Current Report |